Browsing by Subject "Carcinoma"

Article

Activity and toxicity of GI147211 in breast, colorectal and non-small-cell lung cancer patients: An EORTC-ECSG phase II clinical study

Gamucci, T.; Paridaens, R.; Heinrich, B.; Schellens, J. H. M.; Pavlidis, Nicholas; Verweij, J.; Sessa, Cristiana; Kaye, Stanley B.; Roelvink, M.; Wanders, J.; Hanauske, A. R. (2000)

Background: GI147211 is a water-soluble synthetic analogue of camptothecin showing promising in vivo and in vitro antitumor activity and an acceptable toxicity profile. Patients and methods: Between April 1995 and November ...

Article

Angiogenesis in cancer of unknown primary: Clinicopathological study of CD34, VEGF and TSP-1

Karavasilis, V.; Malamou-Mitsi, Vassiliki D.; Briassoulis, E. Ch; Tsanou, E.; Kitsou, E.; Kalofonos, H. P.; Fountzilas, George; Fotsis, T.; Pavlidis, Nicholas (2005)

Background: Cancer of unknown primary remains a mallignancy of elusive biology and grim prognosis that lacks effective therapeutic options. We investigated angiogenesis in cancer of unknown primary to expand our knowledge ...

Article

Axillary nodal metastases from carcinoma of unknown primary (CUPAx): A systematic review of published evidence

Pentheroudakis, George; Lazaridis, G.; Pavlidis, Nicholas (2010)

Axillary lymph node metastases from adenocarcinoma or poorly differentiated carcinoma of unknown primary (CUPAx) represent a rare clinical entity without consensus on its biology, management and outcome. We systematically ...

Article

Cancer of unknown primary origin

Briassoulis, E. Ch; Pavlidis, Nicholas (1997)

About 3 % of all cancer patients suffer from cancer of unknown primary origin. These patients present with metastatic disease for which a primary site cannot be detected at the time of diagnosis. Sophisticated diagnostic ...

Article

Cancer of unknown primary site

Pavlidis, Nicholas; Pentheroudakis, George (2012)

Cancer of unknown primary site (CUP) is a well recognised clinical disorder, accounting for 3-5 of all malignant epithelial tumours. CUP is clinically characterised as an aggressive disease with early dissemination. ...

Article

Carboplatin alone compared with its combination with epirubicin and cyclophosphamide in untreated advanced epithelial ovarian cancer: A hellenic co-operative oncology group study

Skarlos, Dimosthenis V.; Aravantinos, Gerasimos; Kosmidis, Paraskevas A.; Pavlidis, Nicholas; Gennatas, Constantinos; Beer, M.; Mylonakis, N.; Makrantonakis, P.; Klouvas, G. D.; Karpathios, S.; Linardou, H.; Konstantaras, C.; Fountzilas, George (1996)

We compared, in a multicentric randomised prospective study, the efficacy and toxicity of carboplatin 400 mg/m2 as a single agent (CB) to a combination of carboplatin 300 mg/m2, epirubicin 50 mg/m2 and cyclophosphamide 500 ...

Article

Carboplatin plus paclitaxel in unknown primary carcinoma: A phase II Hellenic Cooperative Oncology Group Study

Briassoulis, E. Ch; Kalofonos, H. P.; Bafaloukos, Dimitrios; Samantas, E.; Fountzilas, George; Xiros, N.; Skarlos, Dimosthenis V.; Christodoulou, C.; Kosmidis, Paraskevas A.; Pavlidis, Nicholas (2000)

Purpose: To evaluate the efficacy of the carboplatin/paclitaxel combination in patients with carcinoma of unknown primary site (CUP). Patients and Methods: Seventy-seven consecutive CUP patients (45 women and 32 men; median ...

Article

Carcinoma of unknown primary (CUP)

Pavlidis, Nicholas; Fizazi, K. (2009)

Carcinoma of unknown primary (CUP) is one of the 10 most frequent cancers worldwide. It constitutes 3-5% of all human malignancies. Patients with CUP present with metastases without an established primary site. CUP manifests ...

Article

Carcinoma of unknown primary: Natural history and treatment. Analysis of 30 cases and review of the literature

Pavlidis, Nicholas; Sourla, A.; Ch, F. Tolis; Theoharis, N. M.; Nikolaou, N. (1990)

In this study, the natural history and therapeutic management of 30 patients with carcinoma of unknown primary (CUP syndrome) is presented. Despite detailed laboratory investigations, the primary occult tumor was not ...

Article

Cavitating squamous cell lung carcinoma-distinct entity or not? Analysis of radiologic, histologic, and clinical features

Pentheroudakis, George; Kostadima, Lida; Fountzilas, George; Kalogera-Fountzila, Anna; Klouvas, G. D.; Kalofonos, H. P.; Pavlidis, Nicholas (2004)

Introduction: Patients with cavitating squamous lung carcinoma (cSLC) are believed to harbor aggressive, chemoresistant disease with distinct features and fare poorly. We retrospectively analyzed radiologic, histologic, ...

Article

CENP-B specific anti-centromere autoantibodies heralding small-cell lung cancer. A case study and review of the literature

Briassoulis, E. Ch; Kamposioras, K.; Tzovaras, V.; Pafitanis, G.; Kostoula, A.; Mavridis, A. K.; Pavlidis, Nicholas (2008)

We report on a small-cell lung cancer case that was heralded by the presence of CENP-B specific anti-centromere autoantibodies (ACA) detected well before the diagnosis of cancer. The patient received chemotherapy plus ...

Article

Chemotherapy for patients with two favourable subsets of unknown primary carcinoma: Active, but how effective?

Pentheroudakis, George; Briassoulis, E. Ch; Karavasilis, V.; Fountzilas, George; Xeros, N.; Samelis, G.; Samantas, E.; Pavlidis, Nicholas (2005)

Carcinoma of unknown primary (CUP) is characterized by dismal patient survival. The outcome of patients with two favourable risk CUP subsets was studied. Eighty patients diagnosed with either midline lymph node metastases ...

Article

Cisplatin/etoposide versus carboplatin/etoposide chemotherapy and irradiation in small cell lung cancer: A randomized phase III study

Kosmidis, Paraskevas A.; Samantas, E.; Fountzilas, George; Pavlidis, Nicholas; Apostolopoulou, F.; Skarlos, Dimosthenis V. (1994)

The efficacy and toxicity of cisplatin/etoposide and carboplatin/etoposide combinations along with thoracic irradiation were prospectively assessed in patients with small cell lung cancer. Both combinations were equally ...

Article

Clinical value of CA 15-3, mucin-like carcinoma-associated antigen, tumor polypeptide antigen, and carcinoembryonic antigen in monitoring early breast cancer patients

Pectasides, Dimitrios; Pavlidis, Nicholas; Gogou, L.; Antoniou, F.; Nikolaides, C.; Tsikalakis, D.; Fountzilas, George (1996)

A total of 209 postsurgical breast cancer patients were prospectively monitored with simultaneous serum level estimations of CA 15-3, mucin-like carcinoma-associated antigen (MCA), tumor polypeptide antigen (TPA), and ...

Article

Clinicopathological study of metallothionein immunohistochemical expression, in benign, borderline and malignant ovarian epithelial tumors

Zagorianakou, N.; Stefanou, D. G.; Makrydimas, G.; Zagorianakou, P.; Briassoulis, E. Ch; Karavasilis, V.; Pavlidis, Nicholas; Agnantis, Niki J. (2006)

Metallothioneins (MTs) are a family of cystein-rich metal-binding proteins, which are expressed in normal cells during fetal and postnatal life but also in a variety of human neoplasms. MT expression in human tumors has ...

Article

Clinicopathological study of the expression of syndecan-1 in invasive breast carcinomas. Correlation with extracellular matrix components

Tsanou, E.; Ioachim, E.; Briassoulis, E. Ch; Charchanti, A.; Damala, K.; Karavasilis, V.; Pavlidis, Nicholas; Agnantis, Niki J. (2004)

Syndecan-1, a cell surface proteoglycan found predominantly on epithelia of mature tissues, binds both extracellular matrix (ECM) components and basic fibroblast growth factor (bFGF) and is implicated in the restriction ...

Article

Combination chemotherapy with low doses of weekly Carboplatin and oral Etoposide in poor risk small cell lung cancer

Samantas, E.; Skarlos, Dimosthenis V.; Pectasides, Dimitrios; Nikolaidis, Pavlos; Kalofonos, H. P.; Mylonakis, N.; Vardoulakis, Th; Kosmidis, Paraskevas A.; Pavlidis, Nicholas; Fountzilas, George (1999)

Sixty patients with poor prognostic features, either with extensive disease (ED) or limited disease (LD) small cell lung cancer (SCLC), were treated on an out-patient basis with Carboplatin 80 mg/m2 weekly for 3 weeks and ...

Article

Combination chemotherapy with paclitaxel and gemcitabine followed by concurrent chemoradiotherapy in non-operable localized non-small cell lung cancer. A Hellenic Cooperative Oncology Group (HeCOG) phase II study

Kosmidis, Paraskevas A.; Fountzilas, George; Baka, S.; Samantas, E.; Dimopoulos, M. A.; Gogas, H.; Skarlos, Dimosthenis V.; Papacostas, P.; Boukovinas, I.; Bakoyiannis, Chris; Pantelakos, P.; Athanassiou, E.; Misailidou, D.; Tsekeris, P.; Pavlidis, Nicholas (2007)

Concurrent chemoradiotherapy has become a standard therapy for locoregionally advanced inoperable non-small cell lung cancer (NSCLC). The purpose of this phase II trial was to evaluate the efficacy and toxicity of concurrent ...

Article

Combination chemotherapy with paclitaxel plus carboplatin versus paclitaxel plus gemcitabine in inoperable non-small cell lung cancer: A phase III randomized study. Preliminary results

Kosmidis, Paraskevas A.; Mylonakis, N.; Dimopoulos, M. A.; Pavlidis, Nicholas; Fountzilas, George; Samantas, E.; Dimitriadis, K.; Kalofonos, H. P.; Tsavdaridis, D.; Skarlos, Dimosthenis V. (2000)

Gemcitabine plus paclitaxel and paclitaxel plus carboplatin are active and well tolerated in patients with advanced non-small cell lung cancer, showing similar rates of response and survival. The Hellenic Cooperative ...

Article

Compression of Pancreatic Tumor Blood Vessels by Hyaluronan Is Caused by Solid Stress and Not Interstitial Fluid Pressure

Chauhan, V.; Boucher, Y.; Ferrone, C.; Roberge, S.; Martin, J.; Stylianopoulos, T.; Bardeesy, N.; DePinho, R.; Padera, T.; Munn, L.; Jain, R. (2014)